ClinicalTrials.gg
TerminatedNCT01370876Updated Dec 10, 2013

Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer

A Phase 2 interventional study of Oxaliplatin in Cancer of the Head and Neck and Neoplasms, Head and Neck, sponsored by Nang Kuang Pharmaceutical Co., Ltd.. Terminated at 1 site in Taiwan. Open to male participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-10.

Sponsored by Nang Kuang Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
company policy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing oxaliplatin in Head and Neck Neoplasms — none open to participants now, none under way, none of them phase 3. Oxaliplatin · Head and Neck Neoplasms.

Planned enrollment
Largest of 11
46 · median 16
Started
2010
the only one that year
Phase 2
11 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Nang Kuang Pharmaceutical Co., Ltd.

Among the 12 studies testing oxaliplatin in Head and Neck Neoplasms, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2010, is one of 11 in phase 2, and was the 12th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

None of the 12 studies testing oxaliplatin in Head and Neck Neoplasms is open now. The open studies under Head and Neck Neoplasms, anywhere →

Where they have run

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 20 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing oxaliplatin in Head and Neck Neoplasms as a file.
02

Study summary

To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer and to assess the safety profile of these treatment regimen.

Read the detailed description

To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer.

To assess the safety profile of these treatment regimen. To evaluate the duration of response of oxaliplatin/5-FU.

03

Conditions studied

  • Cancer of the Head and Neck
  • Neoplasms, Head and Neck

Keywords

  • Oxaliplatin
  • Head and Neck cancer
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have been confirmed squamous cell carcinoma of the head and neck (SCCHN) except nasopharyngeal cancer.
  • Patients must have recurrent or disease and for which curative surgery or radiotherapy do not exist or are no longer effective.
  • Prior to entering the protocol treatment, it has to be more than 6 months interval between previous systemic chemotherapy and protocol treatment.
  • The disease must have been measurable by computed tomographic (CT) scan or MRI (done within 30 days of study entry) and the diameter of the target tumor is at least more than 1 cm.
  • Patients must be 20 years of age and 75 years of age.
  • Patients must have an performance status score 2.
  • Patient's hematologic function, liver function and renal function must meet the eligibility requirements.
  • Patients must sign the .

Exclusion criteria

Exclusion Criteria:

  • Patients with known history to Platinum compounds or to 5-Fluorouracil.
  • Patients with .
  • Patients with bone only.
  • Patients with pregnancy or breast-feeding.
  • Patient with CTC (NCI Common Toxicity Criteria) grade 2 peripheral neuropathy of any cause that is clinically detectable.
  • Patients who have serious concomitant illness that might be aggravated by chemotherapy and other conditions which will be judged by physician's discretion.
  • Patients who are receiving other anticancer cancer drug(s) for SCCHN.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Oxaliplatin/5-FU

    Drug: Oxaliplatin

Interventions

  • Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.

    Also known as: Opatin

06

What researchers measure

Primary outcomes

  1. Objective response rate

    To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer

    Time frame: every 12 weeks

Secondary outcomes

  1. Safety

    To assess number of participants with adverse events of these treatment regimen

    Time frame: Each patient will be followed for 30 days after the last dose of study medication

07

Study locations

1 site
  • Taipei Mackay Memorial Hospital
    Taipei, 104, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Aug 2011 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2011
First posted
Jun 10, 2011
Start
Sep 2010
Primary completionActual
Aug 2011
CompletionActual
May 2012
Last update
Dec 10, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01370876
Lead sponsor
Nang Kuang Pharmaceutical Co., Ltd.
First posted
Jun 10, 2011
Start date
Sep 2010
Primary completion
Aug 2011
Completion
May 2012
Last update
Dec 10, 2013

Study contacts

Chang Yi Fan, M.D.
principal investigator · Taipei Mackay Memorial Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxaliplatin

Start the discussion